Novel peptides for the treatment of multiple sclerosis

Bibliography

• KEEGAN BM, NOSEWORTHY JH: Multiple sclerosis. Annu. Rev Med. (2002) 53:285–302.
   PubMed Web of Science ®Google Scholar
• •Excellent review of the current knowledge on MS pathology and treatment.
   Google Scholar
• HEMMER B, ARCHELOS JJ, HARTUNG HP: New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev Neurosci. (2002) 3:291–301.
   PubMed Web of Science ®Google Scholar
• •Excellent review of the immune basis of MS pathogenesis.
   Google Scholar
• HAINES JL, BRADFORD Y, GARCIA ME et al.: Multiple susceptibility loci for multiple sclerosis. Hum. MM. Genet. (2002) 11:2251–2256.
   PubMed Web of Science ®Google Scholar
• KROGSGAARD M, WUCHERPFENNIG KW, CANELLA B et al.: Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex. J. Exp. Med. (2000) 191:1395–1412.
   PubMedGoogle Scholar
• STEINMAN L: Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron (1999) 24:511–514.
   PubMed Web of Science ®Google Scholar
• LANG HL, JACOBSEN H, IKEMIZU S et al.: A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat. Immunol (2002) 3:940–943.
   PubMed Web of Science ®Google Scholar
• CALABRESI PA: Considerations in the treatment of relapsing-remitting multiple sclerosis. Neurology (2002) 58:S10–S22.
   Google Scholar
• OWENS T: Identification of new therapeutic targets for prevention of CNS inflammation. Expert Opin. Then Targets (2002) 6(2):203–215.
   PubMedGoogle Scholar
• DHIB-JALBUT S: Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology (2002) 58:S3–S9.
   Google Scholar
• SELA M, TEITELBAUM D: Glatiramer acetate in the treatment of multiple sclerosis. Expert Opin. Pharmacother. (2001) 2(7):1149–1165.
   PubMedGoogle Scholar
• FRIDKIS-HARELI M, STERN IN, FUGGER L, STROMINGERJL: Synthetic peptides that inhibit binding of the myelin basic protein 85-99 epitope to multiple sclerosis-associated HLA-DR2 molecules and MBP-specific T-cell responses. Hum. Immunol (2001) 62:753–763.
   PubMedGoogle Scholar
• ••Publication of data presented in W002059143.
   Google Scholar
• NEUHAUS O, FARINA C, WEKERLE H, HOHLFELD R: Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology (2001) 56:702–708.
   PubMed Web of Science ®Google Scholar
• KIPNIS J, SCHWARTZ M: Dual action of glatiramer acetate (Cop-1) in the treatment of CNS autoimmune and neurodegenerative disorders. Trends MM. Med. (2002) 8:319–323.
   PubMed Web of Science ®Google Scholar
• KARANDIKAR NJ, CRAWFORD MP, YAN X et al.: Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J. Clin. Invest. (2002) 109:641–649.
   PubMed Web of Science ®Google Scholar
• FLECHTER S, VARDI J, POLLAK L, RABEY JM: Comparison of glatiramer acetate (Copaxone) and interferonI3- lb (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up. J. Neuro. Sci. (2002) 197:51–55.
   PubMed Web of Science ®Google Scholar
• POLLMANN W, ERASMUS LP, FENEBERG W, BERGH FT, STRAUBE A: Interferon 13 but not glatiramer acetate therapy aggravates headaches in MS. Neurology (2002) 59:636–639.
   PubMed Web of Science ®Google Scholar
• WIENDL H, HOHLFELD R: Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs (2002) 16:183–200.
   PubMed Web of Science ®Google Scholar
• LOCK C, HERMANS G, PEDOTTI R et al: Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. (2002) 8:500–508.
   PubMed Web of Science ®Google Scholar
• STEINMAN L, MARTIN R, BERNARD C, CONLON P, OKSENBERG JR: Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu. Rev Neurosci. (2002) 25:491–505.
   PubMed Web of Science ®Google Scholar
• •Review of latest findings in MS pathogenesis that suggest new therapeutic approaches.
   Google Scholar
• SMITH KJ, PYRDOL J, GAUTHIER L, WILEY DC, WUCHERPFENNIG KW: Crystal structure of HLA-DR2 (DRA•0101, DRB1•1501) complexed with a peptide from human myelin basic protein. J. Exp. Med. (1998) 188:1511–1520.
   PubMed Web of Science ®Google Scholar
• ••Structural analysis of the interaction ofMBP 85–99 with HLA-DR2 providing the basis for rational design of HLA-DR2 antagonists.
   Google Scholar
• FRIDKIS-HARELI M, NEVEU JM, ROBINSON RA et al.: Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules. J. Immunol (1999) 162:4697–4704.
   PubMed Web of Science ®Google Scholar
• MADSEN LS, ANDERSSON EC, JANSSON L et al.: A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat. Genet. (1999) 23:343–347.
   PubMed Web of Science ®Google Scholar
• AUSUBEL LJ, KWAN CK, SETTE A, KUCHROO V, HAFLER DA: Complementary mutations in an antigenic peptide allow for crossreactivity of autoreactive T-cell clones. Proc. Natl. Acad. Sci. USA (1996) 93:15317–15322.
   PubMed Web of Science ®Google Scholar
• BIELEKOVA B, MARTIN R: Antigen-specific immunomodulation via altered peptide ligands. I Mol. Med. (2001) 79:552–565.
   PubMed Web of Science ®Google Scholar
• BIELEKOVA B, GOODWIN B, RICHERT N et al.: Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. (2000) 6:1167–1175.
   PubMed Web of Science ®Google Scholar
• KAPPOS L, COMI G, PANITCH H et al.: Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat. Med. (2000) 6:1176–1182.
   PubMed Web of Science ®Google Scholar
• RUIZ PJ, DEVOSS JJ, NGUYEN LV et al: Immunomodulation of experimental autoimmune encephalomyelitis with ordered peptides based on MHC-TCR binding motifs. J. Immunol (2001) 167:2688–2693.
   PubMedGoogle Scholar
• ••Rational design of a peptide antagonist ofHLA-DR2 which ameliorates EAE in rats.
   Google Scholar
• FARINA C, VARGAS V, HEYDARI N et al.: Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients. J. Neurimmund (2002) 123:188–192.
   PubMed Web of Science ®Google Scholar
• FRIDKIS-HARELI M, SANTAMBROGIO L, STERN JN et al: Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis. J. Clin. Invest. (2002) 109:1635–1643.
   PubMed Web of Science ®Google Scholar
• ••Follow-up of studies presented inW002059143, which describes amino acid copolymers more effective than Cop-1 in suppressing EAE in mice.
   Google Scholar
• LUBLIN F, CUTTER G, ELFONT R et al: A trial to assess the safety of combining therapy with interferon-la and glatiramer acetate in patients with relapsing MS. Neurology (2001) 56 (Suppl. 3):A148.
   Google Scholar
• SOOS JM, STUVE O, YOUSSEF S et al: Oral type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate. Immunol (2002) 169:2231–2235.
   Google Scholar
• FUSCO C, ANDREONE V, COPPOLA G et al: HLA-DRB1•1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis. Neurology (2001) 57: 1976-1979.
   Google Scholar
• •Evidence suggesting that Cop-1 is most effective in MS patients that are HLA-DR2+.
   Google Scholar
• OLEK MJ, SMITH DJ, COOK SL, KHOURY SJ, WEINER HL: Phase 1 study of oral recombinant ovine interferon-tau in relapsing-remitting multiple sclerosis. Neurology (2001) 56 (Suppl. 3) :A76.
   Google Scholar
• ICHIKAWA M, KOH CS, INOUE A et al:Anti-IL-12 antibody prevents the development and progression of multiple sclerosis-like relapsing-remitting demyelinating disease in NOD mice induced with myelin oligodendrocyte glycoprotein peptide. .1 Neuroimmuna (2000) 102:56–66.
   Google Scholar
• DALTON C, O'CONNOR P, RICE G et al.: Natalizumab treatment for relapsing MS: further results of a randomized, double-blind, placebo-controlled trial. American Academy of Neurology Meeting, Denver CO, USA (2002) Abstr. S23.003.
   Google Scholar
• MORELAND LW, ALTEN R, VAN DEN BOSCH F et al.: Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. (2002) 46:1470–1479.
   Google Scholar
• MAKHLOUF K, WEINER HL, KHOURY SJ: Potential of 132-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs(2002) 16:1–8.
   PubMed Web of Science ®Google Scholar
• PETTE M, MURARO PA, PETTE DF et al.: Differential effects of phosphodiesterase type 4-specific inhibition on human autoreactive myelin-specific T cell clones. J. Neuroimmunol (1999) 98:147–156.
   PubMedGoogle Scholar
• BRUNMARK C, RUNSTROM A, OHLSSON L et al.: The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J. Neuroimmunol (2002) 130:163–172.
   PubMed Web of Science ®Google Scholar
• NEUHAUS O, STRASSER-FUCHS S, FAZEKAS F et al.: Statins as immunomodulators: comparison with interferon-beta lb in MS. Neurology (2002) 59:990–997.
   PubMed Web of Science ®Google Scholar
• YOUSSEF S, STUVE O, PATARROYO JC et al: The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature (2002) 420:78–84.
   PubMed Web of Science ®Google Scholar